Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients

Zijing Ran, Xiaomei Xue, Lin Han, Robert Terkeltaub, Tony R. Merriman, Ting Zhao, Yuwei He, Can Wang, Xinde Li, Zhen Liu, Lingling Cui, Hailong Li, Aichang Ji, Shuhui Hu, Jie Lü, Changgui LiFrontiers in Endocrinology 2021 · DOI

TL;DR

This study found that lowering serum urate (SU) levels through urate-lowering therapy (ULT) in male gout patients is associated with a significant reduction in visceral fat area (VFA). This suggests that ULT might be a novel therapeutic avenue for managing abdominal obesity in this population.

What Problem Does This Paper Address?

Gout, characterized by high serum urate (hyperuricemia), is increasingly prevalent and often co-occurs with obesity, particularly visceral adiposity. Visceral fat is a known contributor to metabolic dysfunction and cardiovascular disease. While urate-lowering therapy (ULT) is standard for gout management, its potential impact on visceral fat reduction has not been well-established. Previous research has hinted at a correlation between hyperuricemia and visceral fat accumulation, but direct evidence linking SU reduction via ULT to VFA loss in gout patients was lacking. This paper aims to fill that gap by investigating this relationship.

Methods

The researchers conducted a retrospective longitudinal study analyzing data from 237 male gout patients who had at least two body composition and metabolic measurements within a six-month period. All patients were undergoing urate-lowering therapy (ULT) with either febuxostat or benzbromarone. The core of their analysis involved using multiple linear regression to evaluate the relationship between the change in serum urate (ASU) and the change in visceral fat area (AVFA) from baseline to the final visit. They also performed simple linear regression to explore associations with other metabolic parameters and medical history.

Datasets

The study utilized data from the Biobank Information Management System (BIMS) of the Affiliated Hospital of Qingdao University, which contains clinical electronic medical records. This dataset included body composition measurements (visceral fat area, body fat, skeletal muscle mass, etc.) and various metabolic markers (serum urate, glucose, lipids, etc.) from 237 male gout patients.

Key Insights and Ideas

  • ULT as a potential tool for visceral fat reduction: The most significant insight is the direct association found between a decrease in serum urate levels and a reduction in visceral fat area. This suggests that the primary mechanism of ULT might extend beyond just managing gout symptoms to positively impacting abdominal obesity.
  • Visceral fat, not just general obesity, is key: The study specifically focused on visceral fat, highlighting its importance as a metabolic risk factor. The findings suggest that ULT's effect is more pronounced on this deep abdominal fat compared to overall body fat or other measures.
  • Baseline visceral fat matters: The study found that patients with higher baseline visceral fat area experienced a greater reduction in VFA with ULT. This implies that ULT might be particularly beneficial for individuals with more significant visceral adiposity.
  • Mechanism of action: While not definitively proven, the paper speculates that the urate-lowering effect itself, rather than the specific type of ULT agent (febuxostat vs. benzbromarone), drives the VFA reduction. This points towards the direct impact of reduced urate levels on adipocyte function.

Key Results

  • ULT led to a significant decrease in serum urate levels (mean decrease of 103.29 µmol/L, p < 0.001).
  • This decrease in SU was accompanied by a significant reduction in visceral fat area (median decrease of 6.4 cm², p < 0.001).
  • Multiple linear regression analysis identified the change in serum urate (ASU) as a significant determinant of the change in visceral fat area (AVFA) (beta = 0.302, p = 0.001), even after adjusting for baseline VFA and other potential confounders.
  • Patients in the highest quartile of SU decrease (Q4, >189 µmol/L) showed a statistically significant greater reduction in VFA compared to those with smaller SU decreases.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective nature: This study design does not allow for definitive cause-and-effect conclusions.
  • Single-center and single-ethnic: The findings may not be generalizable to diverse populations, including women.
  • Lack of dietary and physical activity data: Changes in diet and exercise habits during the study period could influence VFA and confound the results.
  • Ignoring ULT dosage and duration details: The analysis treated ULT as a whole, without detailing the specific impact of different dosages or treatment durations on VFA.

Future work suggested includes prospective clinical trials to confirm these findings and to further investigate the precise mechanisms by which ULT promotes visceral fat loss. Evaluating the impact of ULT duration and dosage on VFA improvement is also recommended.

Summary updated

Abstract

The decrease in SU level is positively associated with reduced VFA. This finding provides a rationale for clinical trials to affirm whether ULT promotes loss of visceral fat in patients with gout.
BibTeX
@inproceedings{ran2021decrease,
  author = {Zijing Ran and Xiaomei Xue and Lin Han and Robert Terkeltaub and Tony R. Merriman and Ting Zhao and Yuwei He and Can Wang and Xinde Li and Zhen Liu and Lingling Cui and Hailong Li and Aichang Ji and Shuhui Hu and Jie Lü and Changgui Li},
  title = {{Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients}},
  booktitle = {Frontiers in Endocrinology},
  year = {2021},
  doi = {10.3389/fendo.2021.724822},
}
Figure